Increased hepatotoxicity of tumor necrosis factor–related apoptosis‐inducing ligand in diseased human liver
Explore this paper's citation graph
Summary
Clinical trials should be performed with great caution when TRAIL is combined with chemotherapy or administered to patients with inflammatory liver diseases, and enhanced sensitivity of diseased liver was associated with an increased expression of TRAIL receptors and up‐regulation of proapoptotic Bcl‐2 proteins.
- Type
- article
- Published
- 2007-11-01
- Cited by
- 148
- References
- 56
- Access
- Open access
- OpenAlex
- https://openalex.org/W1967554392
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:22994124
Keywords
Apoptosis, Tumor necrosis factor alpha, Hepatology, In vivo, Cancer research
References
- Hepatocyte function and extracellular matrix geometry: long‐term culture in a sandwich configuration
- Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake
- Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo
- TRAIL receptor-2 signals apoptosis through FADD and caspase-8
- TRAIL Induces Apoptosis and Inflammatory Gene Expression in Human Endothelial Cells 1
- IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression.
- Isolated hepatocytes - past, present and future
- Regulation of hepatocyte cell cycle progression and differentiation by type I collagen structure.
- Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
- Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
- Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury
- Anticancer activities of histone deacetylase inhibitors
- Caspase‐10 is recruited to and activated at the native TRAIL and CD95 death‐inducing signalling complexes in a FADD‐dependent manner but can not functionally substitute caspase‐8
- Is TRAIL hepatotoxic?
- Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection
- Potential and caveats of TRAIL in cancer therapy.
- Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity
- Histological grading and staging of chronic hepatitis.
- Dysregulation of Apoptosis as a Mechanism of Liver Disease: An Overview
- New Hepatocyte In Vitro Systems for Drug Metabolism: Metabolic Capacity and Recommendations for Application in Basic Research and Drug Development, Standard Operation Procedures
Cited by
- TRAIL and other TRAIL receptor agonists as novel cancer therapeutics.
- Apoptosis in the aging liver
- Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands.
- Effect of senescent secreted factors on neoplastic transformation and sensitization to TRAIL
- Hepatitis C Virus Infection Sensitizes Human Hepatocytes to TRAIL-Induced Apoptosis in a Caspase 9-Dependent Manner1
- Human natural killer cell activation and differentiation in health and viral infection
- Effect of coumarin and diallyl polysulfides on HCT116 colon cancer cells
- Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles
- Carbon monoxide inhibits apoptosis during cold storage and protects kidney grafts donated after cardiac death
- Coinfection With HIV-1 and HCV—A One-Two Punch
- Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy
- Thirteen-week Intravenous Toxicity Study of a Novel Humanized Anti-Human Death Receptor 5 Monoclonal Antibody, CS-1008, in Cynomolgus Monkeys
- Midkine secretion protects Hep3B cells from cadmium induced cellular damage.
- Systemic Tumor-Specific Gene Delivery
- BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma
- The TRAIL apoptotic pathway in cancer onset, progression and therapy
- Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
- Is TRAIL the holy grail of cancer therapy?
- Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study
- Oxidative stress sensitizes bladder cancer cells to TRAIL-mediated apoptosis by downregulating anti-apoptotic proteins
Related papers
- Hepatology and Transplant Hepatology
- HEPATOLOGY and hepatology: The good, the bad, and the ugly
- The downstream financial effect of hepatology
- Clinical hepatology: Alcoholic liver disease, not viral hepatitis, predominates in South Wales
- Special Chapter: A Scan of Hepatology in Asia Pacific Region
- Endo-hepatology: a new paradigm.
- Hepatology training in the UK
- Patterns of service utilisation within Australian hepatology clinics: high prevalence of advanced liver disease